Vardenafil Hydrochloride Tablet, Film Coated
Product Images NDC 46708-238

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Vardenafil Hydrochloride (NDC 46708-238). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

30 Tablets (Vardenafil 10mg)

The packaging label for Vardenafil Hydrochloride Tablets by Alembic Pharmaceuticals Limited displays a 10 mg strength film-coated oral tablet in a 30-tablet package. It includes dosage description, storage recommendations, and a barcode, with warnings about color additives and child-resistant packaging.*

FDA Label Image

30 Tablets (Vardenafil 2 5mg)

Label for Vardenafil Hydrochloride Tablets 2.5 mg by Alembic Pharmaceuticals Limited. The label includes the NDC 46708-236-30 and indicates a package of 30 film-coated tablets for oral use. It provides storage recommendations, dosage instructions, and mentions color additives used in the tablets. The label also features a barcode and manufacturer details from India.*

FDA Label Image

30 Tablets (Vardenafil 20mg)

Vardenafil Hydrochloride Tablets 20 mg film-coated oral tablets package label shows 30 tablets. The label includes the NDC 46708-239-30, Rx only designation, Alembic Pharmaceuticals Limited as the labeler, and storage instructions. The label notes color additives including FD&C Yellow No. 5 (tartrazine) and dosage guidance to take one tablet as needed.*

FDA Label Image

30 Tablets (Vardenafil 5mg)

Vardenafil Hydrochloride Tablets 5 mg film-coated oral tablets in a package of 30. The label includes NDC 46708-237-30 and is produced by Alembic Pharmaceuticals Limited. The label lists storage recommendations and notes the tablet contains color additives including FD&C Yellow No. 5 (tartrazine).*

FDA Label Image

Figure 1 (Vardenafil Figure1)

A set of three line graphs showing the mean maximal change in systolic blood pressure (mmHg), diastolic blood pressure (mmHg), and heart rate (bpm) over time points labeled 24h, 8h, 4h, and 1h. The x-axis represents timing of vardenafil treatment prior to NTG, with error bars present on each data point.*

FDA Label Image

Figure 2 (Vardenafil Figure2)

A line graph showing mean change in mmHg over time in hours up to 6 hours. It compares blood pressure changes with placebo and Vardenafil 5 mg under simultaneous and 6-hour separation dosing conditions, with four distinct lines indicating each group’s mean changes over time.*

FDA Label Image

Figure 3 (Vardenafil Figure3)

A line graph depicting mean change in mmHg over 6 hours comparing placebo and vardenafil 5 mg under simultaneous and 6-hour separation conditions. The x-axis represents time in hours, and the y-axis shows mean change in mmHg. Four data series are plotted with distinct markers for each treatment condition.*

FDA Label Image

Figure 4 (Vardenafil Figure4)

A line graph depicting mean change in mmHg over time in hours (0 to 6) for placebo and Vardenafil at 10 mg and 20 mg doses. Separate lines represent placebo at two stages and Vardenafil at two strengths, showing trends in mean change measurements over the 6-hour period.*

FDA Label Image

Figure 5 (Vardenafil Figure5)

A line chart showing mean change in mmHg over time (0 to 6 hours) for placebo and vardenafil 5 mg and 10 mg groups in two stages. The graph includes four data series comparing blood pressure changes with placebo in stages 1 and 2, and vardenafil at 5 mg and 10 mg doses, illustrating trends in mean change over time.*

FDA Label Image

Figure 6 (Vardenafil Figure6)

A line graph titled Terazosin showing the mean change in mmHg over a 6-hour period. It compares placebo, 10 mg vardenafil, and 20 mg vardenafil under both 6-hour separation and simultaneous administration conditions, with multiple lines representing different groups tracked over time from 0 to 6 hours.*

FDA Label Image

Figure 7 (Vardenafil Figure7)

This chart depicts the mean change in mmHg over time (hours) of Tamsulosin under different conditions with placebo and varying doses of Vardenafil (10 mg and 20 mg). It shows data for both 6-hour separation and simultaneous administration. The x-axis represents time in hours, and the y-axis shows mean change in mmHg.*

FDA Label Image

Figure 8 (Vardenafil Figure8)

A pharmacokinetic graph showing plasma concentration (µg/L) of vardenafil hydrochloride over time (hours) after oral administration. The curve peaks early and gradually declines, demonstrating the drug's absorption and elimination profile, with error bars indicating variability at each time point.*

FDA Label Image

Structure (Vardenafil Str)

Chemical structure diagram of vardenafil hydrochloride, showing its molecular components including a piperazine ring, sulfonamide group, and other characteristic features representing the active ingredient vardenafil hydrochloride.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.